ImmunoRestoration, Inc. logo

ImmunoRestoration, Inc.

ImmunoRestoration, Inc. is a clinical-stage biopharmaceutical company developing immunotherapeutic cancer vaccine platform for the treatment of multiple types of cancer especially breast cancer.

ImmunoRestoration was founded to lead the development and commercialization of a novel immunotherapeutic cancer vaccine platform based on research and studies done at the University of Pennsylvania; led by Drs. Brian Czerniecki and Gary Koski.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://www.immunorestoration.com
Founded2016
Disease Focus
Development StageClinical
STOCK CODENon Listed
Address
1410 West Street Road,18974
Warminster
United States
Email
Contact Number
+1 215-345 1530

ImmunoRestoration, Inc. is a clinical-stage biopharmaceutical company developing immunotherapeutic cancer vaccine platform for the treatment of multiple types of cancer especially breast cancer.

ImmunoRestoration was founded to lead the development and commercialization of a novel immunotherapeutic cancer vaccine platform based on research and studies done at the University of Pennsylvania; led by Drs. Brian Czerniecki and Gary Koski.

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

The companys core technology is a novel, integrated dendritic cell-based immunization system – Immune Conditioning via Activated Innate (autologous) Transfer – ICAIT©, that helps patients battle cancer by rejuvenating their own immune response. It uses dendritic cells (DC) as liaison cells between the T cells and the other cells of the immune system to oversome obstacles facing anti-cancer vaccines.

In Nov 2018, ImmunoRestoration acquired further clinical developmental rights of BB-IND-11043 from Dr. Brian Czerniecki, MD., Ph.D, of the H. Lee Moffitt Cancer Center & Research Institute. The vaccine has been used in more than 100 women with encouraging results, with ImmunoRestoration planning for the upcoming new multi-center, multi-year trials for further platforms development.